Systemic inflammatory response syndrome Not Applicable Systemic inflammatory response syndrome
Conditions
Interventions
Infusions of either tranexamic acid or placebo (0.9% saline), with doses of 2 g pre- and post-cardiopulmonary bypass after protamine administration.
Follow-up continued until the patient was dischar
Sponsors
University Hospital of Canary Islands (Consorcio Sanitario de Tenerife [CST]) (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consecutive Caucasian adults undergoing elective cardiopulmonary bypass surgery with normal aggregation and coagulation test values.
Exclusion criteria
Exclusion criteria: 1. Emergency interventions 2. Patients with a history of haemostatic dysfunction 3. Renal failure (creatinine greater than 2 mg/dL) 4. Chronic hepatopathy 5. Immunodepressed patients 6. Sepsis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the efficacy of tranexamic acid in decreasing the incidence of systemic inflammatory response syndrome and postoperative bleeding. Data was recorded preoperatively, after surgery, at Intensive Care Unit admission (0 hours), four hours and 24 hours. | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the efficacy of tranexamic acid to reduce excessive postoperative bleeding in patients undergoing cardiac surgery, according to the presence of different genotypes of the Plasminogen Activator Inhibitor (PAI-1) gene. Data was recorded preoperatively, after surgery, at Intensive Care Unit admission (0 hours), four hours and 24 hours. | — |
Countries
Spain
Outcome results
None listed